Orlistat
Xenical
Sources
registry, as of 2020-04-07Stale
https://clinicaltrials.gov/study/NCT01755676
Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults. Overall status COMPLETED. Phases PHASE3. Lead sponsor EMS. Enrollment 638. Conditions Obesity. The purpose of this study is to evaluate efficacy of orlistat 60 mg as adjuvant treatment of Obesity in adults.
ClinicalTrials.gov NCT01755676 protocol and results modules
registry, as of 2022-02-03Stale
https://clinicaltrials.gov/study/NCT02432209
Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility. Overall status COMPLETED. Phases PHASE3. Lead sponsor Yale University. Enrollment 379. Conditions Infertility, Female. A two-arm, multicenter, prospective, randomized clinical trial of a lifestyle modification program with tracked increased physical activity and weight loss (intensive) compared to recommendations to tracking of increased physical activity alone with weight maintenance (standard) deaths Intensive Lifestyle Mod. Intervention 0 diarrhea Intensive Lifestyle Mod. Intervention 35 deaths Standard Lifestyle Intervention 0 diarrhea Standard Lifestyle Intervention 9
ClinicalTrials.gov NCT02432209 protocol and results modules
registry, as of 2016-04-05Stale
https://clinicaltrials.gov/study/NCT00940628
A Study of Xenical (Orlistat) in Overweight and Obese Adolescents. Overall status COMPLETED. Phases PHASE3. Lead sponsor Hoffmann-La Roche. Enrollment 60. Conditions Obesity. This 2 arm study will assess the effect of Xenical on body mass index (BMI)in obese or overweight adolescents. Patients will be randomised into one of 2 groups; both groups will undergo a regimen of mildly hypocaloric diet and physical exercise, but one group will also receive Xe
ClinicalTrials.gov NCT00940628 protocol and results modules
registry, as of 2011-02-23Stale
https://clinicaltrials.gov/study/NCT01047657
Effects of Weight Loss in Obese Difficult-to-treat Asthmatics. Overall status COMPLETED. Phases PHASE3. Lead sponsor University of Sao Paulo General Hospital. Enrollment 33. Conditions Asthma; Obesity; Weight Loss. Sixty percent of patients with difficult to control asthma seen in our outpatient clinic are obese. The impact of weight reduction in this subpopulation of asthmatics has not been studied. Our aim is to evaluate the impact of weight reduction on asthma control of these patients.
ClinicalTrials.gov NCT01047657 protocol and results modules
registry, as of 2006-08-29Stale
https://clinicaltrials.gov/study/NCT00156897
Efficacy and Safety of ATL-962 in Obese Diabetics. Overall status COMPLETED. Phases PHASE2. Lead sponsor Alizyme. Enrollment 600. Conditions Non-Insulin-Dependent Diabetes Mellitus; Obesity. The purpose of this study is to investigate whether ATL-962 induces weight loss in diabetic patients and whether its safety and tolerability profile is superior to that of orlistat in such patients
ClinicalTrials.gov NCT00156897 protocol and results modules
registry, as of 2018-05-09Stale
https://clinicaltrials.gov/study/NCT01126970
Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects. Overall status COMPLETED. Phases PHASE2. Lead sponsor Shionogi. Enrollment 486. Conditions Obesity. To evaluate the weight loss effect and safety of 400 mg velneperit and 120 mg orlistat administered individually or combined three times per day for 24 weeks while on a reduced calorie diet (RCD) and also to evaluate the steady-state trough concentrations of velneperit (S-2367),
ClinicalTrials.gov NCT01126970 protocol and results modules
registry, as of 2024-02-20Stale
https://clinicaltrials.gov/study/NCT05934110
Study Exploring the Supportive Effect of Acarbose in Weight Management. Overall status UNKNOWN. Phases PHASE2. Lead sponsor Empros Pharma AB. Enrollment 320. Conditions Overweight or Obesity. This is a randomized, double-blind study in participants with overweight or obesity in which the effect of acarbose and the impact of dose on efficacy, safety and tolerability is investigated by comparing the EMP16 combination product with modified release (MR) orlistat, orlistat
ClinicalTrials.gov NCT05934110 protocol and results modules
registry, as of 2012-12-18Stale
https://clinicaltrials.gov/study/NCT00001723
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases. Overall status COMPLETED. Phases PHASE2. Lead sponsor Jack Yanovski. Enrollment 200. Conditions Diabetes Mellitus; Hypertension; Metabolic Disease; Obesity; Sleep Apnea Syndrome. Obesity is a condition affecting one-third off the U.S. population and is a major risk actor for the development of Type 2 diabetes, hyperlipidemia (increased levels of fat in the blood), hypertension (high blood pressure), and other disorders of the heart and lungs. Individuals diarrhea Orlistat 21 nausea Orlistat 10 vomiting Orlistat 7 diarrhea Placebo 8 nausea Placebo 9 vomiting Placebo 7
ClinicalTrials.gov NCT00001723 protocol and results modules
registry, as of 2022-04-04Stale
https://clinicaltrials.gov/study/NCT04521751
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary). Overall status COMPLETED. Phases PHASE1,PHASE2. Lead sponsor Empros Pharma AB. Enrollment 156. Conditions Overweight or Obesity. This study is a proof of concept study to demonstrate that EMP16-02, a fixed dose combination (FDC) of orlistat and acarbose in an oral multiple-unit modified release (MR) formulation leads to a clinically relevant decrease in body weight. The study aims to evaluate the efficacy,
ClinicalTrials.gov NCT04521751 protocol and results modules
registry, as of 2018-08-17Stale
https://clinicaltrials.gov/study/NCT02069197
Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea. Overall status UNKNOWN. Phases PHASE2. Lead sponsor Mid-Atlantic Epilepsy and Sleep Center, LLC. Enrollment 150. Conditions Obesity; Diabetes; Obstructive Sleep Apnea. The purpose of the study is to evaluate the efficacy and safety of ketogenic diet (KD) treatment of (i) obesity, (ii) type 2 diabetes mellitus and (iii) obstructive sleep apnea (OSA) in patients with obesity and Type 2 DM and in patients with obesity and/or OSA. This will be a ra
ClinicalTrials.gov NCT02069197 protocol and results modules
registry, as of 2026-03-12Stale
https://clinicaltrials.gov/study/NCT01351753
Drug Therapy Induced Weight Loss to Improve Blood Vessel Function in Subjects With Obesity. Overall status TERMINATED. Phases PHASE2. Lead sponsor University of Iowa. Enrollment 128. Conditions Obesity; Metabolic Syndrome X. Obesity is common (\>30% of US adults), contributes to substantial morbidity and mortality, but is difficult to treat. Partly this is due to the transient, arduous and modest nature of lifestyle interventions. Partly it is due to the limited efficacy and safety problems of existi
ClinicalTrials.gov NCT01351753 protocol and results modules
registry, as of 2021-04-01Stale
https://clinicaltrials.gov/study/NCT01003483
Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients. Overall status COMPLETED. Phases PHASE2. Lead sponsor Yazd Research & Clinical Center for Infertility. Enrollment 80. Conditions Obesity. The purpose of this study is to compare the influence of Orlistat and Metformin on obesity treatment in obese PCOS women.
ClinicalTrials.gov NCT01003483 protocol and results modules
fda, as of 2026-11-07
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6240792b-9224-2d10-e053-2a91aa0a2c3e
t identified an increased risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. However, weight loss offers no benefit to a pregnant patient and may result in a small for gestational age infant. When a pregnancy is recognized, advise the pregnant patient of the
DailyMed xenical, indication text
publication, as of 2026-10-12Stale
https://pubmed.ncbi.nlm.nih.gov/42855032/
Digestive lipases as therapeutic targets in obesity: From Orlistat to next-generation inhibitors. Obesity remains a global pandemic and a major driver of metabolic diseases, with current pharmacotherapies often limited by modest efficacy, systemic side effects, high costs, an
PMID 42855032